Market Overview:
The global uterine polyps drug market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of uterine polyps, rising awareness about available treatment options, and growing demand for minimally invasive procedures. By type, the oral segment is expected to account for the largest share of the global uterine polyps drug market in 2018. This segment is projected to grow at a CAGR of 6% during the forecast period. By application, hospital-based care is expected to account for the largest share of the global uterine polyps drug market in 2018.
Product Definition:
Uterine polyps are benign tumors that grow on the inner lining of the uterus. They can be small or large and may cause bleeding, pain, and infertility. Uterine polyps are most often treated with a surgical procedure called a hysterectomy.
Oral:
Oral is a drug that is used for the treatment of uterine polyps. It works by shrinking the size of the uterus and making it non-viable. Oral has no effect on an existing pregnancy, but can be given to a woman who is not pregnant.
Injection:
Injection is a medical procedure used to treat uterine polyps. It works by shrinking the tumor and may also prevent it from growing back. In some cases, surgery may be an option but it depends upon the type of polyps and other factors.
Application Insights:
Based on application, the global uterine polyps drug market is segmented into hospital, clinic or healthcare center, homecare and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to increasing prevalence of high-risk conditions and rising number of surgeries being performed for this condition. According to data published by NCBI in 2018, around 1% to 3% women get affected by Uterine Polyps each year globally.
The homecare segment is expected to witness significant growth over the forecast period due to growing awareness about available treatment options among patients across various regions including North America and Europe. Increasing adoption of advanced diagnostic techniques such as transvaginal ultrasound scan has led many women with symptoms such as heavy menstrual bleeding along with abdominal pain seek medical consultation at an early stage which eventually helps reduce mortality rate among patients suffering from uterine polyps significantly over a span of time.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of uterine polyps and the availability of effective treatment methods are some factors responsible for its largest share. The region is expected to maintain its position during the forecast period due to increasing R&D investments by various companies and rising healthcare expenditure.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving economic conditions, growing awareness about early diagnosis, presence of target population (young & middle-aged women), increase in disposable income levels, and rise in medical tourism activities across countries such as China & India & Malaysia etc. In addition, favorable government initiatives pertaining to quality healthcare services are also expected drive regional growth during the estimated time span from 2018 - 2030 (See Table 1).
Growth Factors:
- Increasing incidence of uterine polyps
- Growing awareness about the available treatment options for uterine polyps
- Rising demand for minimally invasive procedures to treat uterine polyps
- Technological advancements in the field of hysteroscopy and laparoscopy that are making surgical treatments for uterine polyps more effective and less invasive
- Growing number of women opting for preventive surgery to reduce their risk of developing complications associated with uterine polyps
Scope Of The Report
Report Attributes
Report Details
Report Title
Uterine Polyps Drug Market Research Report
By Type
Oral, Injection, Other
By Application
Hospital, Clinic, Homecare, Other
By Companies
GSK, Roche, Pfizer, Novartis, Merck, Bristol-Myers, Sanofi, Teva Pharmaceutical Industries, Amgen, Mylan, Sun Pharmaceutical Industries
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Uterine Polyps Drug Market Report Segments:
The global Uterine Polyps Drug market is segmented on the basis of:
Types
Oral, Injection, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Homecare, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Roche
- Pfizer
- Novartis
- Merck
- Bristol-Myers
- Sanofi
- Teva Pharmaceutical Industries
- Amgen
- Mylan
- Sun Pharmaceutical Industries
Highlights of The Uterine Polyps Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- Other
- By Application:
- Hospital
- Clinic
- Homecare
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Uterine Polyps Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Uterine polyps are benign growths on the uterus that can occur in women of all ages. Uterine polyps are usually small, but they can occasionally become larger and cause pain or difficulty during intercourse. Treatment options include surgery to remove the polyp, radiation therapy, or a combination of these two treatments.
Some of the major companies in the uterine polyps drug market are GSK, Roche, Pfizer, Novartis, Merck, Bristol-Myers, Sanofi, Teva Pharmaceutical Industries, Amgen, Mylan, Sun Pharmaceutical Industries.
The uterine polyps drug market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Uterine Polyps Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Uterine Polyps Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Uterine Polyps Drug Market - Supply Chain
4.5. Global Uterine Polyps Drug Market Forecast
4.5.1. Uterine Polyps Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Uterine Polyps Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Uterine Polyps Drug Market Absolute $ Opportunity
5. Global Uterine Polyps Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Uterine Polyps Drug Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Injection
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Uterine Polyps Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Uterine Polyps Drug Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Homecare
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Uterine Polyps Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Uterine Polyps Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Uterine Polyps Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Uterine Polyps Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Uterine Polyps Drug Demand Share Forecast, 2019-2026
9. North America Uterine Polyps Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Uterine Polyps Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Uterine Polyps Drug Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Homecare
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Uterine Polyps Drug Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Injection
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Uterine Polyps Drug Demand Share Forecast, 2019-2026
10. Latin America Uterine Polyps Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Uterine Polyps Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Uterine Polyps Drug Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Homecare
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Uterine Polyps Drug Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Injection
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Uterine Polyps Drug Demand Share Forecast, 2019-2026
11. Europe Uterine Polyps Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Uterine Polyps Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Uterine Polyps Drug Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Homecare
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Uterine Polyps Drug Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Injection
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Uterine Polyps Drug Demand Share, 2019-2026
12. Asia Pacific Uterine Polyps Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Uterine Polyps Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Uterine Polyps Drug Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Homecare
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Uterine Polyps Drug Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Injection
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Uterine Polyps Drug Demand Share, 2019-2026
13. Middle East & Africa Uterine Polyps Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Uterine Polyps Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Uterine Polyps Drug Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Homecare
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Uterine Polyps Drug Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Injection
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Uterine Polyps Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Uterine Polyps Drug Market: Market Share Analysis
14.2. Uterine Polyps Drug Distributors and Customers
14.3. Uterine Polyps Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Roche
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Merck
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Sanofi
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Teva Pharmaceutical Industries
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Amgen
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Mylan
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Sun Pharmaceutical Industries
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
